



Docket No.: 784

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Auerback et al.

Serial No.: 10/705,432 **Group:** 1632

Filing Date: 10 November 2003 **Examiner:** Montanari, David A.

Title: METHOD OF IMPROVING GENE TARGETING USING A UBIQUITIN PROMOTER

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450.

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Fees

No fee is required for the filing of this Information Disclosure Statement.
If any additional fee should be deemed necessary, the Commissioner is hereby
authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Tor SMELAND
Reg. No. 43,131
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400